JPRN-UMIN000000613已完成2 期
Phase II study of a combination of CPT-11, 5FU/l-LV and UFT/LV in patients with advanced/recurrent colorectal cancer - OGSG0605
Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)0 个研究点目标入组 40 人开始时间: 2007年3月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)interstitial pneumonitis or pulmonary fibrosis 2)with cavity fluid to be treated 3)with present active double cancer or D.B. diagnosed less than 5 years before, excluding cured cancer in situ or skin cancer 4)ileus 5)watery diarrhea 6)D.M. which needs insulin or uncontrolled D.M. 7)With other diseases which influence to the study (heart diseases, liver dysfunction, renal failure) 8)brain metastasis with some symptoms 9)pregnant women or suspected women 10)receiving atazanavir sulfate 11)Receiving steroids treatment 12)With experience of drug anaphylaxis shock 13)Doctor stop due to miscellaneous factors
研究者
相似试验
已完成
2 期
PhaseII study of 5-FU/I-LV+L-OHP+CPT-11 combination chemotherapy(FOLFIRINOX) in 1st line treatment for locally advanced pancreatic cancerlocally advanced pancreatic cancerJPRN-UMIN000013385Osaka Medical College Hospital45
未知
2 期
Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal CancerJPRN-jRCT1080220199Taiho Pharmaceutical Co., Ltd. DAIICHI SANKYO Co., Ltd.
已完成
2 期
Phase II study of a combination of modified CPT-11 and 5-FU/l-LV (mJIFL) in patients with meatastatic colorectal cancerMeatastatic colorectal cancerJPRN-UMIN000000727OGSG54
已完成
不适用
Phase II study of Combination of CPT-11 and S-1 for Advanced Non-Small-cell lung cancerPreviously untreated stageIIIB/IV NSCLCJPRN-C000000415West Japan Oncology Group55
已完成
2 期
Phase II study of a combination of CPT-11 and S-1 and Panitumumab in patients with KRAS wild-type metastatic colon cancer.KRAS wild-type metastatic colon cancer.JPRN-UMIN000005368iigata Colorectal cancer Chemotherapy Study Group (NCCSG)25